Expression of c-Jun and Sox-2 in human schwannomas and traumatic neuromas

Histopathology

Volumn 62, Issue 4, 2013, Pages 651-656

  Shivane, Aditya ^a   Parkinson, David B ^b   Ammoun, Sylwia ^b   Hanemann, Clemens O ^b  

^a DERRIFORD HOSPITAL   (United Kingdom)

^b PLYMOUTH UNIVERSITY PENINSULA SCHOOLS OF MEDICINE AND DENTISTRY   (United Kingdom)

Author keywords

C Jun; Immunohistochemistry; Schwannoma; Sox 2; Traumatic neuroma

Indexed keywords

PROTEIN C JUN; TRANSCRIPTION FACTOR SOX2;

ARTICLE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NERVE CELL PLASTICITY; NERVE FIBER; NEURILEMOMA; NEUROMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRAUMATIC NEUROMA;

HUMANS; NEURILEMMOMA; NEUROMA; PERIPHERAL NERVE INJURIES; PERIPHERAL NERVES; PROTO-ONCOGENE PROTEINS C-JUN; SOXB1 TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84874216954     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12062     Document Type: Article

References (26)

1. Jessen KR, Mirsky R. The origin and development of glial cells in peripheral nerves. Nat. Rev. Neurosci. 2005; 6; 671-682.
2. Mirsky R, Jessen KR. The neurobiology of Schwann cells. Brain Pathol. 1999; 9; 293-311.
3. Mirsky R, Jessen KR. Origin and early development of Schwann cells. Microsc. Res. Tech. 1998; 41; 393-402.
4. Le N, Nagarajan R, Wang JY et al. Nab proteins are essential for peripheral nervous system myelination. Nat. Neurosci. 2005; 8; 932-940.
5. Doddrell RD, Dun XP, Moate RM, Jessen KR, Mirsky R, Parkinson DB. Regulation of Schwann cell differentiation and proliferation by the Pax-3 transcription factor. Glia. 2012; 60; 1269-1278.
6. He Y, Kim JY, Dupree J et al. Yy1 as a molecular link between neuregulin and transcriptional modulation of peripheral myelination. Nat. Neurosci. 2010; 13; 1472-1480.
7. Nagarajan R, Svaren J, Le N, Araki T, Watson M, Milbrandt J. EGR2 mutations in inherited neuropathies dominant-negatively inhibit myelin gene expression. Neuron 2001; 30; 355-368.
8. 2-terminal kinase/c-jun to control Schwann cell proliferation and death. J. Cell Biol. 2004; 164; 385-394.
9. Topilko P, Schneider-Maunoury S, Levi G et al. Krox-20 controls myelination in the peripheral nervous system. Nature 1994; 371; 796-799.
10. Britsch S, Goerich DE, Riethmacher D et al. The transcription factor Sox10 is a key regulator of peripheral glial development. Genes Dev. 2001; 15; 66-78.
11. Parkinson DB, Bhaskaran A, Arthur-Farraj P et al. C-jun is a negative regulator of myelination. J. Cell Biol. 2008; 181; 625-637.
12. Mirsky R, Jessen KR. Negative regulation of myelination: relevance for development, injury, and demyelinating disease. Glia 2008; 56; 1552-1565.
13. Arthur-Farraj PJ, Latouche M, Wilton DK et al. c-Jun reprograms Schwann cells of injured nerves to generate a repair cell essential for regeneration. Neuron 2012; 75; 633-647.
14. Fontana X, Hristova M, Da Costa C et al. c-Jun in Schwann cells promotes axonal regeneration and motoneuron survival via paracrine signaling. J. Cell Biol. 2012; 198; 127-141.
15. Taranova OV, Magness ST, Fagan BM et al. SOX2 is a dose-dependent regulator of retinal neural progenitor competence. Genes Dev. 2006; 20; 2654-2659.
16. Lo/Lo nerves identifies Sox2 as an inhibitor of Schwann cell differentiation and myelination. Proc. Natl Acad. Sci. USA 2005; 102; 2596-2601.
17. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO classification of tumours of the central nervous system. 4th ed. Lyon: IARC, 2007; 152-155.
18. Hanemann CO. Magic but treatable? tumours due to loss of Merlin. Brain. 2008; 131; 606-615.
19. Curto M, Cole BK, Lallemand D, Liu CH, McClatchey AI. Contact-dependent inhibition of EGFR signalling by NF2/Merlin. J. Cell Biol. 2007; 177; 893-903.
20. Morrison H, Sperka T, Manent J, Giovannini M, Ponta H, Herrlich P. Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac. Cancer Res. 2007; 67; 520-527.
21. Hung G, Colton J, Fisher L et al. Immunohistochemistry study of human vestibular nerve schwannoma differentiation. Glia 2002; 38; 363-370.
22. Utemark T, Kaempchen K, Antoniadis G, Hanemann CO. Reduced apoptosis rates in human schwannomas. Brain Pathol. 2005; 15; 17-22.
23. Rosenbaum C, Kamleiter M, Grafe P et al. Enhanced proliferation and potassium conductance of Schwann cells isolated from NF2 schwannomas can be reduced by quinidine. Neurobiol. Dis. 2000; 7; 483-491.
24. Hilton DA, Ristic N, Hanemann CO. Activation of ERK, AKT and JNK signalling pathways in human schwannomas in situ. Histopathology 2009; 55; 744-749.
25. Kaempchen K, Mielke K, Utermark T, Langmesser S, Hanemann CO. Upregulation of the Rac 1/JNK signalling pathway in primary human schwannoma cells. Hum. Mol. Genet. 2003; 12; 1211-1221.
26. Kamachi Y, Uchikawa M, Kondoh H. Pairing SOX off: with partners in the regulation of embryonic development. Trends Genet. 2000; 16; 182-187.